Cargando…

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

BACKGROUND: The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellular cytotoxicity (ADCC) induced by type I/II anti-CD20 antib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albertsson-Lindblad, Alexandra, Freiburghaus, Catja, Jerkeman, Mats, Ek, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685275/ https://www.ncbi.nlm.nih.gov/pubmed/31406628 http://dx.doi.org/10.1186/s40164-019-0141-1

Ejemplares similares

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
por: Freiburghaus, Catja, et al.
Publicado: (2018)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2021)

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter’s Syndrome
por: Heyman, Benjamin M., et al.
Publicado: (2022)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017)

P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY
por: Husby, S., et al.
Publicado: (2022)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
por: Ekberg, Sara, et al.
Publicado: (2022)

Bortezomib/ibrutinib/rituximab: Various toxicities: case report
Publicado: (2021)

The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2022)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Obinutuzumab/rituximab: Decreased platelet count and chronic COVID-19 pneumonia: case report
Publicado: (2020)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
por: Khurana, Sharad, et al.
Publicado: (2019)

Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
por: Kvacskay, Peter, et al.
Publicado: (2022)

Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
por: Reddy, Venkat R, et al.
Publicado: (2021)

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
por: Lamar, Zanetta, et al.
Publicado: (2015)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report
por: Lachowiez, Curtis, et al.
Publicado: (2017)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
por: Van Sanden, Suzy, et al.
Publicado: (2017)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
por: Dartigeas, Caroline, et al.
Publicado: (2022)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lpg1heg43hkuufb843n6efm87